Description
Specifications Table
Product Name – 2-Hydroxy Propyl Beta Cyclodextrine for Synthesis
Quantity/Pack Size – 25 gm, 100 gm
Form – Powder
Grade – Lab/Reagent
Application – Molecular encapsulation, drug delivery, chromatography
Product Overview
2-Hydroxy Propyl Beta Cyclodextrine (HP-β-CD) is a modified cyclodextrin derivative designed for high-performance lab applications. Its hydrophobic cavity enhances solubility and stability, making it ideal for molecular encapsulation, drug delivery systems, and analytical chemistry. This lab-grade reagent ensures purity and consistency, suitable for researchers and educators. HP-β-CD’s unique structure allows it to form inclusion complexes with hydrophobic molecules, improving their aqueous solubility and bioavailability. Its non-toxic and biocompatible nature makes it a preferred choice for pharmaceutical and biochemistry studies. The powder form ensures easy handling and precise measurements, while its high-grade purity minimizes contamination risks. Whether for academic research or industrial synthesis, this cyclodextrin derivative delivers reliable performance.
FAQs
1. What is the primary use of 2-Hydroxy Propyl Beta Cyclodextrine?
It is primarily used for molecular encapsulation, drug delivery, and chromatography due to its ability to form stable inclusion complexes.
2. Is this product suitable for pharmaceutical research?
Yes, its biocompatibility and solubility-enhancing properties make it ideal for pharmaceutical and biochemistry applications.
3. How should this cyclodextrin be stored?
Store in a cool, dry place away from direct sunlight and moisture to maintain its stability and purity.
4. Can this be used in food-grade applications?
This specific grade is intended for lab and synthesis use. For food-grade applications, check the product specifications.
5. What are the alternatives to 2-Hydroxy Propyl Beta Cyclodextrine?
Alternatives include native beta-cyclodextrin or other modified cyclodextrins like methyl-beta-cyclodextrin, depending on the application.
